Company intelligence / Profile preview

MetVital, Inc.

San Diego, California, United Statesmetvital.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

MetVital's lead drug candidate, Anhydrous Enol-Oxaloacetate (AEO), received FDA Fast Track Designation for treatment of newly diagnosed glioblastoma multiforme. The company has a Phase 2 clinical trial for GBM patients. Their compounds have demonstrated safety and efficacy in animal models with human glioblastoma tissue implants, ALS, and Alzheimer's disease[3][5].

Therapeutic areas: OncologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

KetoPrime

Unknown

Beyond the preview

Go deeper on MetVital, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetVital, Inc..

Explore the full profile